OBJECTIVE： To evaluate the pharmacoeconomics of cefathiamidine， ceftriaxone sodium， cefuroxime sodium， amoxicillin sodium/clavulanate potassium and cefoperazone sodium/sulbactam sodium in the treatment of pediatric bronchopneumonia， and to provide reference for rational drug use in the clinic. METHODS： By retrospective study， 338 children with bronchopneumonia were divided into groups A， B， C， D and E according to different therapy regimens. There were 75， 65， 76， 66 and 56 cases in groups A， B， C， D and E， and they were given cefathiamidine， ceftriaxone sodium， cefuroxime sodium， amoxicillin sodium/clavulanate potassium and cefoperazone sodium/sulbactam sodium intravenously. The pharmacoeconomics of therapy regimens in group A， B， C， D and E were evaluated by cost-effectiveness analysis and decision tree analysis model. RESULTS： The effective rates of groups A， B， C， D and E were 93.33％， 90.77％， 96.05％， 87.88％ and 87.50％， respectively. The treatment cost of those groups were 1 929.09， 2 173.73， 1 611.91， 1 661.42， 1 801.32 yuan， respectively. The cost/effectiveness （C/E） ratio of those groups were 20.67， 23.95， 16.78， 18.91， 20.59， respectively. The treatment cost of group C was the smallest， so was the C/E. Results of cost-effectiveness analysis were supported by sensitivity analysis. CONCLUSIONS： Cefuroxime sodium is the best treatment for pediatric bronchopneumonia among 5 antibiotics in respect of cost-effectiveness.